Valneva reports the subjects in Phase II clinical trial of Lyme disease vaccine develop antibodies. The results were positive enough to inspire Pfizer to join with Valneva to continue testing in the next phase of clinical trials and, hopefully, bring this to market. Find out more about the vaccine strategy and Lyme disease:
Read More
Pfizer and Valneva Join Forces on Lyme Disease Vaccine
One Step Closer to a Lyme Disease Vaccine
Related Reading in BioSerendipity
New Hope for Lyme Disease Prevention